Valuation: Vaxart, Inc.

Market Cap 133M 115M 107M 98.48M 185M 12.65B 188M 1.26B 493M 6.33B 499M 488M 20.95B P/E 2026 *
-3.44x
P/E 2027 * -0.65x
Enterprise Value 133M 115M 107M 98.48M 185M 12.65B 188M 1.26B 493M 6.33B 499M 488M 20.95B EV / Sales 2026 *
1.62x
EV / Sales 2027 * 28.3x
Free-Float
97.95%
Yield 2026 *
-
Yield 2027 * -
1 day+0.63%
1 week+11.83%
Current month+11.83%
1 month+9.74%
3 months-18.39%
6 months-0.51%
Current year+74.34%
1 week 0.53
Extreme 0.5302
0.64
1 month 0.44
Extreme 0.44
0.64
Current year 0.34
Extreme 0.3434
0.84
1 year 0.3
Extreme 0.305
0.84
3 years 0.26
Extreme 0.2606
1.54
5 years 0.26
Extreme 0.2606
10.33
10 years 0.25
Extreme 0.2543
24.9
Manager TitleAgeSince
Chief Executive Officer 60 18/03/2024
Chief Tech/Sci/R&D Officer 59 01/03/2024
Director of Finance/CFO - 19/05/2025
Director TitleAgeSince
Director/Board Member 68 21/04/2021
Director/Board Member 76 04/08/2022
Director/Board Member 79 01/01/2022
Date Insider Type Main position Quantity % Market Cap.
16/07/26 Free

Director

118,100 0.0488%
16/07/26 Free

Director

118,100 0.0488%
16/07/26 Free

Director

118,100 0.0488%
Change 5-day change 1-year change 3-year change Capi.($)
+0.63%+11.83%+54.62%-16.12% 133M
+8.49%+20.55%+69.74%+109.30% 68.12B
+1.25%+2.44%+32.55%+72.63% 55.18B
-1.09%+32.96%+19.95%+499.45% 28.63B
+2.72%+3.41%-15.88%-4.90% 23.53B
+10.83%+18.38%+52.76%+4.58% 23.99B
+6.50%+7.56%+38.20%-21.33% 18.45B
-3.88%+16.98%+199.30%+354.30% 15.83B
+6.20%+11.51%+34.94%+681.88% 16.44B
+3.58%+1.96%+44.61%+167.01% 13.4B
Average +3.52%+10.51%+53.08%+184.68% 26.37B
Weighted average by Cap. +4.35%+13.09%+49.48%+168.40%

Financials

2026 *2027 *
Net sales 81.8M 70.78M 66.07M 60.65M 114M 7.79B 116M 775M 304M 3.9B 307M 300M 12.9B 4.7M 4.07M 3.8M 3.48M 6.55M 447M 6.65M 44.53M 17.46M 224M 17.65M 17.26M 741M
Net income -165M -143M -133M -122M -230M -15.69B -233M -1.56B -612M -7.86B -619M -605M -26B -222M -192M -179M -164M -309M -21.09B -314M -2.1B -823M -10.57B -832M -814M -34.95B
Net Debt - -
Logo Vaxart, Inc.
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The Company's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen.
Employees
65
Date Price Change Volume
07/08/26 $0.5505 -3.42% 201,629
06/08/26 $0.5700 -3.31% 181,566
05/08/26 $0.5895 -1.75% 283,704
04/08/26 $0.6000 +1.69% 321,732
03/08/26 $0.5900 +9.27% 280,925
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.5505USD
Average target price
3.333USD
Spread / Average Target
+505.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VXRT Stock